Ride the megatrend with "Gufic Biosciences Limited" (GBSL), an India-based company operating in four business segments: formulations, bulk drugs, consumer products and agro products.
Fundamentals supporting it be a potential multibagger:
The Indian healthcare sector is expected to reach US$ 372 billion by 2024, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. Gufic bio is one of the company to get benefit of the megatrend.
Gufic Biosciences has done good performance over a period of time,
It has a Debt to Equity ratio of 1.16 , which is a strong indication for the company.
Its cash from the operating activity was Rs 45.69 Cr.
Gufic Biosciences have a healthy ROE of 26.70 %
It has a high promoter holding of 65.75%.
Company has good cash flow
Technicals:
Cup and handle pattern breakout with significant vol
MACD above signal and center
RSI Indicating price strength
"All you need for a lifetime of successful investing is a few big winners, and the pluses from those will overwhelm the minuses from the stocks that don’t work out.” – Peter Lynch